Serum Epeidermal Growth Factor Receptor (EGFR) in Cervical Cancer.
- Author:
Chung Hyun LIM
;
Yong Ho LEE
;
Yoon Jung CHO
;
Nak Woo LEE
;
Young Tae KIM
;
Kyu Wan LEE
- Publication Type:Original Article
- Keywords:
Cervical carcinoma;
epidermal gmwth factor receptor;
serum;
enzyme-linked immunosorbent assay
- MeSH:
Breast;
Carcinoma, Squamous Cell;
Cervix Uteri;
Enzyme-Linked Immunosorbent Assay;
Esophagus;
Female;
Humans;
Lung;
Prognosis;
Receptor, Epidermal Growth Factor;
Stomach;
Uterine Cervical Neoplasms*
- From:Korean Journal of Gynecologic Oncology and Colposcopy
2000;11(1):67-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Epidermal growth factor receptor (EGFR) is overexpressed in various malignancies including carcinoma of the breast, lung, esophagus, cervix, and stomach. In patients with cervical carcinoma, its overexpression may be associated with advanced stage and poor prognosis. So, we evaluated the levels of serum EGFR in patients with cervical carcinoma. The level of EGFR extracellular domain was determined in serum from 57 cervical carcinoma patients(adenocarcinoma: 2, squamous cell carcinoma: 39, carcinoma in situ(CIS): 16) and 28 cases of healthy control using enzyme-linked immunosorbent assay(Calbiochem). In invasive carcinoma, serum EGFR level was measured in 11 cases of Stage Ia, 9 cases of Stage Ib, 4 cases of Stage IIa, 15 cases of Stage IIb, 2 cases of stage III patients. The mean ages of the healthy controls, of the wome with carcinoma in situ(CIS), and with invasive cervical carcinoma were not different(49.3, 44,4, 49.5, respectively, p 0.241). The mean serum level of EGFR in healthy control(n 28), carcinoma in situ(CIS)(n 16), and invasive carcinoma patients(n=41) were not significantly different(71.4+/-12.8fmol/ml, 79.2+/-26.8fmol/ml, 61.8+/- 18.4 fmol/ml, respectively, p=0.071). In conclusion, the expression of EGFR was not increased in patients with cervical cancer compared with normal women. And no significant differences were found depending on the clinical stage.
